logo-loader
viewOncimmune

Oncimmune Roche collaboration expanded substantially

"Our ongoing relationship with Roche is providing us with the opportunity to further contribute to the understanding of individual patient responses to immunotherapy through immune profiling,” said chief executive, Dr Adam Hill

Oncimmune -

Oncimmune Holdings PLC (LON:ONC) said there has been a “substantial expansion” of its collaboration with Swiss giant Roche – one which will see the value of its contract increase.

The immunodiagnostics specialist’s biomarker discovery platform SeroTag is being used to “explore the baseline and on-treatment autoantibody profiles as biomarkers in patients that received cancer immunotherapy”.

The timeline for the project has not changed, with initial results to be provided to Roche within three months of completion in November.

"Our ongoing relationship with Roche is providing us with the opportunity to further contribute to the understanding of individual patient responses to immunotherapy through immune profiling,” Oncimmune chief executive, Dr Adam Hill said in a statement.

While financial details weren’t provided, Oncimmune said in May the contract involved a substantial upfront payment.

“Importantly, we are delighted to see the substantial value that Oncimmune can contribute to major pharmaceutical and biotechnology companies,” said CEO Hill.

“With the number of partners utilising our ImmunoINSIGHTS service continuing to grow, I look forward to announcing future projects in the coming few months." 

Quick facts: Oncimmune

Price: 137.5 GBX

AIM:ONC
Market: AIM
Market Cap: £87.33 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20

2 min read